Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2012 AGM of Orion Corporation

Orion Corporation        Stock Exchange Release        30 January 2012        at
12.35  EET

The Nomination Committee of Orion Corporation has given on 30 January 2012 its
recommendation to the Board of Directors of the company for the proposal to the
Annual General Meeting of 2012 concerning the composition of the Board of
Directors to be elected. The Committee recommends that the following proposal be
presented to the AGM of 2012:

The number of Board members would be six. Of the present members, Sirpa
Jalkanen, Eero Karvonen, Hannu Syrjänen, Heikki Westerlund and Jukka Ylppö would
be re-elected and Timo Maasilta, M.Sc. (Tech.) would be elected as a new member
for the next term of office. Hannu Syrjänen would be re-elected as Chairman.

Of the present members, Matti Kavetvuo has reached the age of 67 and therefore
cannot be elected member of the Board of Directors according to the Articles of
Association.

Timo Maasilta, M.Sc. (Tech.), born 1954, is the Managing Director of an
investment company Tukinvest Oy and the Managing Director of Maa- ja
vesitekniikan tuki ry. He has over 25 years experience in management and board-
level positions. Maasilta holds many positions of trust, among others Chairman
of the Board of Directors of Maa- ja vesitekniikan tuki ry and Chairman of the
Board of Directors of Tuen Kiinteistöt Oy. Between 1991 and 2002, he was a
Member of the Supervisory Board of Orion Corporation and between 2004 and 2011
the Chairman of the Nomination Committee of Orion Corporation. His earlier
positions of trust include among others board memberships in Amer Sports
Corporation, Ompus Inc. and Amer Cultural Foundation.

The Nomination Committee also announces as its recommendation that the following
remunerations be paid to the Board of Directors:

As an annual fee for the term of office of the Board of Directors, the Chairman
would receive EUR 76,000, the Vice Chairman would receive EUR 51,000 and the
other members would receive EUR 38,000 each. As a fee for each meeting attended,
the Chairman would receive EUR 1,200, the Vice Chairman would receive EUR 900
and the other members would receive EUR 600 each. The travel expenses of the
Board members would be paid in accordance with previously adopted practice. The
aforementioned fees would also be paid to the Chairmen and to the members of the
committees established by the Board, for each committee meeting attended.

Of the annual fee, 60% would be paid in cash and 40% in Orion Corporation B-
shares, which would be acquired to the members during 26-30 March 2012 from the
stock exchange in amounts corresponding to EUR 30,400 for the Chairman, EUR
20,400 for the Vice Chairman and EUR 15,200 for each of the other members. The
part of the annual fee that is to be paid in cash corresponds to the approximate
sum necessary for the payment of the income taxes on the fees and would be paid
no later than 30 April 2012. The annual fees shall encompass the full term of
office of the Board of Directors.

The Nomination Committee has not given its recommendation for the remunerations
to the Board of Directors, but the matter will be proposed by a shareholder at
the AGM of 2012.

The Nomination Committee has consisted of the following members: Matti
Kavetvuo,Chairman, Kari Jussi Aho, Timo Ritakallio, Seppo Salonen, Hannu
Syrjänen and Jukka Ylppö.


Orion Corporation


Timo Lappalainen  Olli Huotari
President and CEO Senior Vice President, Corporate Functions


Contact person:

Matti Kavetvuo, Chairman of the Nomination Committee of Orion Corporation, phone
+358 50 591 0744






Publisher:
Orion Corporation
www.orion.fi


Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, oncology and critical care drugs, and Easyhaler®
pulmonary drugs.

The Group's net sales in 2010 amounted to EUR 850 million. The Company invested
EUR 86 million in research and development. At the end of 2010, the Group had
about 3,100 employees, of whom 2,500 worked in Finland and the rest in other
countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

[HUG#1581022]